AUTEM THERAPEUTICS RAISES $10 MILLION SERIES A-1 FINANCING FOR NOVEL BIOELECTRIC CANCER TREATMENT PLATFORM

0
28

Hanover, NH and Sao Paulo, Brazil, June 06, 2022 (GLOBE NEWSWIRE) — Autem Therapeutics LLC (“Autem Therapeutics” or “the Company”), an emerging oncology therapeutic and bioelectric technology company, has announced the completion of its $10 million Series A-1 financing round. The round was led by Zentynel Frontier Investments with other new and existing investors participating.

 The company also announced the appointment of Michael Choukas as Chief Executive Officer. Michael is a life sciences executive and entrepreneur with broad enterprise experience serving in leadership roles across the strategic, operational and commercial functions of leading global healthcare companies, including United BioSource (UBC), Oncopartners, Vector Oncology, and most recently as President, Outcomes Science and Services at Concerto HealthAI (now ConcertAI). He brings to the role a proven track record of success building companies that have contributed to over $2.5BN in market value creation.

 Autem Therapeutics is developing a novel bioelectric oncology treatment platform targeting Hepatocellular Carcinoma (HCC) and other solid tumor cancers. The company has received FDA breakthrough designation for the treatment of advanced HCC (liver cancer) patients. The Company’s AutEMsys™ therapy delivers personalized, amplitude-modulated electromagnetic (EM) frequencies to patients systemically. Data from initial clinical feasibility studies involving 66 HCC patients suggest that amplitude modulated EM frequencies may be effective in shrinking cancerous tumors, enhancing quality of life and extending survival in patients with early and advanced stage HCC.

 Proceeds from the Series A-1 round will fund the completion of Autem’s next generation AutEMsys™ technology and related testing and validation, the US FDA Investigational Device Exemption (IDE) and European and Latin American regulatory submissions and approvals to initiate clinical trials, and the start-up phase of the HCC pivotal trial.

 Autem Therapeutics’ CEO, Michael Choukas stated: “I’m excited to lead Autem’s global management team which brings together experienced professionals with complementary expertise in oncology clinical practice and research, bio-physics, software development and AI, and bio-pharmaceutical and medical device operations and executive management.”  “Our team is passionate about developing a non-invasive, non-toxic, globally accessible cancer treatment to enhance the outcomes and lives of cancer patients worldwide”.

 Cristian Hernandez, MBE, Zentynel’s partner leading the investment added, “Autem Therapeutics technology combines physics, artificial intelligence, biology and medicine to create better cancer treatments. We are proud to empower a company that we believe will radically transform cancer treatment globally and improve the lives of thousands of people who currently have limited treatment options”.

  

ABOUT AUTEM THERAPEUTICS 

Autem Therapeutics is a privately held oncology therapeutic and bioelectric company headquartered in Hanover NH, USA that is developing a novel, non-invasive and non-toxic oncology treatment platform targeting HCC (liver cancer) and other solid tumor cancers.

 The company has received FDA breakthrough designation for its AutEMsys™ therapy for the treatment of advanced HCC patients. The AutEMsys™ therapy delivers personalized, amplitude-modulated electromagnetic (EM) frequencies (and based on initial clinical feasibility studies shows promise in shrinking cancerous tumors, enhancing quality of life and extending survival in early and advanced stage cancer patient populations. Autem Therapeutics anticipates submitting an FDA Investigational Device Exemption (IDE) to initiate FDA pivotal clinical trials in late 2022 or early 2023.

  

ABOUT ZENTYNEL FRONTIER INVESTMENTS

 Zentynel Frontier Investments is a leading Biotech and Life Sciences venture capital fund based in Santiago, Chile, with operations across Latin America. Zentynel is focused on leading the next generation of science and business funds in Latin America. Based on its proven track record, it has assembled a network of world-class partners and advisors to invest in superior companies with outstanding biomedical technology products in emerging markets.

  

Note on Forward-Looking Statements

 Statements made in this news release that are not historical facts are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as anticipates, expects, believes, intends, and similar expressions are intended to identify forward-looking statements. Actual results may differ materially from those projected in any forward-looking statement. Specifically, there are a number of important factors that could cause actual results to differ materially from those anticipated, such as the Company’s ability to raise additional capital, and risks related to the Company’s ability to initiate, and enroll patients in, planned clinical trials. You should not place undue reliance on any forward-looking statements. The Company assumes no obligation to update any forward-looking statements as a result of new information, future events or developments, except as required by law. The Company’s products and technologies have not received regulatory approval for marketing and are not available commercially.